Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2003

London Cheryl A, Hannah Alison L, Zadovoskaya Regina, Chien May B, Kollias-Baker Cynthia, Rosenberg Mona, Downing Sue, Post Gerald, Boucher Joseph, Shenoy Narmada, Mendel Dirk B, McMahon Gerald, Cherrington Julie M

Abstract excerpt

PURPOSE: The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor, SU11654, using a canine model of spontaneous tumors. This p.o. bioavailable compound exhibits potent inhibitory activity against m...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dog Diseases
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Models, Chemical

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Receptor Protein-Tyrosine Kinases

Share to Receptors, Vascular Endothelial Growth Factor

Source

Identifiers

PMID: 12855656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12855656-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.PMID 12855656Read ↗

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.Semantic proximity Read ↗

From the clinic to the bench and back again in one dog year: identifying new treatments for sarcoma using a cross-species personalized medicine pipelineSemantic proximity Read ↗

The Role of Canine Models of Human Cancer: Overcoming Drug Resistance through a Transdisciplinary Approach “One Health, One Medicine”Semantic proximity Read ↗

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.Semantic proximity Read ↗

From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision MedicineSemantic proximity Read ↗

The caninized anti-canine PD-1 monoclonal antibody in canine oral malignant melanoma: Efficacy and exploratory biomarker analysisSemantic proximity Read ↗

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.Semantic proximity Read ↗

Blood and Tissue Biomarker Analysis in Dogs with Osteosarcoma Treated with Palliative Radiation and Intra-Tumoral Autologous Natural Killer Cell TransferSemantic proximity Read ↗

The phosphoinositide 3-kinase pathway is crucial for the growth of canine mast cell tumors.Semantic proximity Read ↗

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancerSemantic proximity Read ↗

Src Continues Aging: Current and Future Clinical DirectionsSemantic proximity Read ↗

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.